Plasma membrane localization signals in the light chain of botulinum neurotoxin

被引:87
作者
Fernández-Salas, E [1 ]
Steward, LE [1 ]
Ho, H [1 ]
Garay, PE [1 ]
Sun, SW [1 ]
Gilmore, MA [1 ]
Ordas, JV [1 ]
Wang, J [1 ]
Francis, J [1 ]
Aoki, KR [1 ]
机构
[1] Allergan Pharmaceut Inc, Dept Biol Sci, Neurotoxin Res Program, Irvine, CA 92612 USA
关键词
SNARE; subcellular localization; dileucine motif; duration of action; Clostridium;
D O I
10.1073/pnas.0400229101
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Botulinum neurotoxin (BoNT) is a potent biological substance used to treat neuromuscular and pain disorders. Both BoNT type A and BoNT type E display high-affinity uptake into motor neurons and inhibit exocytosis through cleavage of the synaptosome-associated protein of 25 kDa (SNAP25). The therapeutic effects of BoNT/A last from 3 to 12 months, whereas the effects of BoNT/E last less than 4 weeks. Using confocal microscopy and site-specific mutagenesis, we have determined that the protease domain of BoNT/A light chain (BoNT/ A-LC) localizes in a punctate manner to the plasma membrane, colocalizing with the cleaved product, SNAP25(197). In contrast, the short-duration BoNT/E serotype is cytoplasmic. Mutations in the BoNT/A-LC have revealed sequences at the N terminus necessary for plasma membrane localization, and an active dileucine motif in the C terminus that is likely involved in trafficking and interaction with adaptor proteins. These data support sequence-specific signals as determinants of intracellular localization and as a basis for the different durations of action in these two BoNT serotypes.
引用
收藏
页码:3208 / 3213
页数:6
相关论文
共 51 条
  • [1] Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle
    Adler, M
    Keller, JE
    Sheridan, RE
    Deshpande, SS
    [J]. TOXICON, 2001, 39 (2-3) : 233 - 243
  • [2] NEF INDUCES CD4 ENDOCYTOSIS - REQUIREMENT FOR A CRITICAL DILEUCINE MOTIF IN THE MEMBRANE-PROXIMAL CD4 CYTOPLASMIC DOMAIN
    AIKEN, C
    KONNER, J
    LANDAU, NR
    LENBURG, ME
    TRONO, D
    [J]. CELL, 1994, 76 (05) : 853 - 864
  • [3] Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety
    Aoki, KR
    [J]. TOXICON, 2002, 40 (07) : 923 - 928
  • [4] BINZ T, 1994, J BIOL CHEM, V269, P1617
  • [5] Di-leucine signals mediate targeting of tyrosinase and synaptotagmin to synaptic-like misrovesicles within PC12 cells
    Blagoveshchenskaya, AD
    Hewitt, EW
    Cutler, DF
    [J]. MOLECULAR BIOLOGY OF THE CELL, 1999, 10 (11) : 3979 - 3990
  • [6] BOTULINUM NEUROTOXIN-A SELECTIVELY CLEAVES THE SYNAPTIC PROTEIN SNAP-25
    BLASI, J
    CHAPMAN, ER
    LINK, E
    BINZ, T
    YAMASAKI, S
    DECAMILLI, P
    SUDHOF, TC
    NIEMANN, H
    JAHN, R
    [J]. NATURE, 1993, 365 (6442) : 160 - 163
  • [7] Genetic analyses of adaptin function from yeast to mammals
    Boehm, M
    Bonifacino, JS
    [J]. GENE, 2002, 286 (02) : 175 - 186
  • [8] A dileucine motif in HIV-1 Nef acts as an internalization signal for CD4 downregulation and binds the AP-1 clathrin adaptor
    Bresnahan, PA
    Yonemoto, W
    Ferrell, S
    Williams-Herman, D
    Geleziunas, R
    Greene, WC
    [J]. CURRENT BIOLOGY, 1998, 8 (22) : 1235 - 1238
  • [9] Brin MF, 2002, SCI THERAPEUTIC ASPE, P233
  • [10] CHADDOCK JA, 2001, MOL MED MICROBIOLOGY, P1141